Selected EMA news, September 2025

New information on approved medicines 

• Lunsumio (mosunetuzumab) – new route of administration / new pharmaceutical form / new strengths
  Treatment of follicular lymphoma (a type of blood cancer) 
• Keytruda (pembrolizumab) – new pharmaceutical form
  Treatment of several types of cancer, including Classical Hodgkin lymphoma 

Withdrawal of applications for new medicines 

• Fanskya (mozafancogene autotemcel)
  Treatment of fanconi anemia type A, an inherited condition that affects the bone marrow, the spongy tissue inside the large bones where blood cells are made